89618-77-9: Bortezomib Impurity 20
It is associate impurity of Bortezomib. Bortezomib is employed to treat people with multiple myeloma (a type of cancer of the bone marrow). bortezomib is during a category of medicines known as antineoplastic agents.
Additional information on CAS 89618-77-9
(3aS, 4S, 6S, 7aR)-2-((S)-1-chloro-2-methylpropyl)-3a, 5, 5-trimethylhexahydro-4, 6-methanobenzo[d][1, 3, 2]dioxaborole
“Sci-Hub, Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile, 10.1208/S12249-010-9554-1.” Hkvisa.net, 2022, sci-hub.hkvisa.net/10.1208/s12249-010-9554-1.
Other products related to bortezomib
|CAS No.||Name of Impurity||Parent Drug||Catalogue No.|